The study provided additional information about the immunologic safety of Recothrom and demonstrated that Recothrom was well tolerated when applied as an aid to hemostasis in patients, including
A definitive agreement will be entered into as soon as possible but no later than January 15, 2009, with closing to occur on or before February 27, 2009
The company may now begin widespread marketing and promotion of Invisalign in Japan, where it has trained approximately 660 Invisalign orthodontists since launching the product there in October,
The supplemental biologics license application (sBLA) submission is based primarily on data from the pivotal, multinational Flex Phase III study which demonstrated that the addition of Erbitux to
The ELuminexx vascular stent is a flexible, self-expanding nitinol stent to be marketed by the Bard peripheral vascular division, located in Tempe, Arizona. The device is intended to
The double-blind study showed that both doses (300mg BID and 450mg BID) of delafloxacin were as efficacious as the FDA approved dosing regime for tigecycline in the treatment
According to the company, Retigabine comprises a new way of affecting potassium channels in the central nervous system. It has been documented to treat epilepsy and has a
The new service is expected to enable fast delivery of clinical trial images through a web accessible, secure network between clinical sites and Bio-Imaging’s Imaging Core Lab (ICL),
One orphan drug designation has been granted for diffuse large B-cell lymphoma and the other one for the treatment of follicular lymphoma. Reviroc is under development for the
The trial demonstrated that the patented lidocaine formulation was able to deliver a significantly greater amount of lidocaine into the localized area of the skin compared to a
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.